Metropolis Clinical Pathology will acquire and operate all laboratories and collection centers of Scientific Pathology in Agra and neighbouring towns through a slump sale transaction
Standalone profit from operations for Q4-2024 were Rs. 108 crore
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
IMCD India’s innovative formulations bring the Skinification trend to life with cutting-edge solutions across beauty and personal care
The company will showcase groundbreaking innovations from its Pharma and Nutrition divisions, highlighting key ingredients and formulations designed to support holistic well-being
EBITDA rose to Rs. 14.8 crore, marking a 16.5% y-o-y increase, while net profit surged to Rs. 6.4 crore
AA Signature provides an innovative approach to treatment planning that focuses on patient outcomes
CDMO business delivered high-teen revenue growth for 9MFY25 driven by continued traction in the on-patent commercial manufacturing and generic API business
The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space
The FDA determined that the data presented in a 2022 color additive petition show that this ingredient causes cancer in male laboratory rats exposed to high levels of FD&C Red No. 3 because of a hormonal mechanism that occurs in male rats
Subscribe To Our Newsletter & Stay Updated
